Valuation : Omeros Corporation

Market Cap 1.32B 1.14B 1.08B 978M 1.84B 126B 1.85B 12.82B 4.93B 64.32B 4.97B 4.86B 203B P/E 2026 *
20.5x
P/E 2027 * 18.3x
Enterprise Value 1.32B 1.14B 1.08B 978M 1.84B 126B 1.85B 12.82B 4.93B 64.32B 4.97B 4.86B 203B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 6.69x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day-1.67%
1 week-3.54%
Current month-2.71%
1 month+34.41%
3 months+79.57%
6 months+53.23%
Current year+6.43%
1 week 18.28
Extreme 18.28
19.55
1 month 16.27
Extreme 16.27
19.65
Current year 6.7
Extreme 6.7023
19.65
1 year 3.94
Extreme 3.94
19.65
3 years 0.92
Extreme 0.92
19.65
5 years 0.92
Extreme 0.92
19.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 1994-06-15
Director of Finance/CFO 62 2024-06-29
Chief Tech/Sci/R&D Officer 70 2019-10-31
Director TitleAgeSince
Chairman 67 1994-06-15
Director/Board Member 86 1994-12-31
Director/Board Member 72 1994-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Exercice

General Counsel

75,000 0.1036%
8/27/26 Exercice

Director

30,000 0.0415%
8/24/26 Exercice

Chief Financial Officer

2,718 0.0038%
Change 5-day change 1-year change 3-year change Capi.($)
-1.67%-3.54%+335.24%+432.17% 1.32B
-2.11%-1.68%+44.52%+95.15% 66.93B
-0.23%-4.45%+30.39%+73.64% 61.97B
+1.67%+2.47%-11.23%+388.34% 28.27B
-1.05%-4.43%+30.56%+10.07% 24.59B
+0.34%-6.78%-7.27%-17.99% 24.3B
+0.43%-3.37%+14.85%-19.29% 19.41B
-3.03%-2.29%+185.12%+334.07% 16.77B
-1.94%-4.94%-5.29%+495.65% 14.18B
-2.28%-4.90%+43.64%+155.21% 13.91B
Average -0.99%-3.46%+66.05%+194.70% 27.17B
Weighted average by Cap. -0.85%-3.07%+34.93%+135.12%

Financials

2026 *2027 *
Net sales 126M 108M 102M 92.88M 174M 12B 175M 1.22B 468M 6.1B 472M 461M 19.29B 198M 170M 161M 146M 274M 18.9B 276M 1.92B 737M 9.61B 743M 727M 30.38B
Net income 63.3M 54.54M 51.64M 46.81M 87.81M 6.05B 88.26M 613M 236M 3.08B 238M 233M 9.72B 79.47M 68.47M 64.83M 58.76M 110M 7.59B 111M 770M 296M 3.86B 298M 292M 12.2B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
26-09-11 $18.28 -1.67% 1,014,308
26-09-10 $18.59 -4.13% 1,231,840
26-09-09 $19.39 +1.41% 1,531,324
26-09-08 $19.12 +0.90% 1,015,537
26-09-04 $18.95 -0.84% 892,192
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
18.28USD
Average target price
33.00USD
Spread / Average Target
+80.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!